Predictive and prognostic value of gene mutations in myelodysplastic syndrome treated with hypomethylating agents: a meta-analysis

References

• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405.
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454–2465.
   PubMed Web of Science ®Google Scholar
• Nazha A, Sekeres MA, Garcia-Manero G, MDS Clinical Research Consortium, et al. Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents. Leuk Res. 2016;41:43–47.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Stahl M, Sekeres MA, et al. A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials. Cancer. 2017;123(19):3662–3672.
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Gerstung M, Malcovati L, Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122(22):3616–3627.
   PubMed Web of Science ®Google Scholar
• Makishima H, Yoshizato T, Yoshida K, et al. Dynamics of clonal evolution in myelodysplastic syndromes. Nat Genet. 2017;49(2):204–212.
   PubMed Web of Science ®Google Scholar
• Awada H, Thapa B, Visconte V. The genomics of myelodysplastic syndromes: Origins of disease evolution, biological pathways, and prognostic implications. Cells. 2020;9(11):2512.
   Web of Science ®Google Scholar
• Sperling AS, Gibson CJ, Ebert BL. The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia. Nat Rev Cancer. 2017;17(1):5–19.
   PubMed Web of Science ®Google Scholar
• Hunter AM, Komrokji RS, Yun S, et al. Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes. Blood Adv. 2021;5(4):1017–1028.
   PubMed Web of Science ®Google Scholar
• Bejar R, Lord A, Stevenson K, et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood. 2014;124(17):2705–2712.
   PubMed Web of Science ®Google Scholar
• Wu P, Weng J, Li M, et al. Co-occurrence of RUNX1 and ASXL1 mutations underlie poor response and outcome for MDS patients treated with HMAs. Am J Transl Res. 2019;11(6):3651–3658.
   PubMed Web of Science ®Google Scholar
• Nazha A, Sekeres MA, Bejar R, et al. Genomic biomarkers to predict resistance to hypomethylating agents in patients with myelodysplastic syndromes using artificial intelligence. J Clin Oncol Precision Oncology. 2019;3(3):1–11.
   Google Scholar
• Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the international working group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419–425.
   PubMed Web of Science ®Google Scholar
• Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.
   PubMed Web of Science ®Google Scholar
• Chen Y-Y, Shi R, Guo S-Q, et al. Outcomes of DNMT3A + myelodysplastic syndrome patients treated with decitabine. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2020;28(4):1292–1297.
   PubMedGoogle Scholar
• Nagata Y, Makishima H, Kerr CM, et al. Invariant patterns of clonal succession determine specific clinical features of myelodysplastic syndromes. Nat Commun. 2019;10(1):5386.
   PubMedGoogle Scholar
• Montalban-Bravo G, Takahashi K, Patel K, et al. Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. Oncotarget. 2018;9(11):9714–9727.
   PubMedGoogle Scholar
• Kuendgen A, Muller-Thomas C, Lauseker M, et al. Efficacy of azacitidine is independent of molecular and clinical characteristics – an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature. Oncotarget. 2018;9(45):27882–27894.
   PubMedGoogle Scholar
• Idossa D, Lasho TL, Finke CM, et al. Mutations and karyotype predict treatment response in myelodysplastic syndromes. Am J Hematol. 2018;93(11):1420–1426.
   PubMed Web of Science ®Google Scholar
• Cabezon M, Bargay J, Xicoy B, CETLAM Group, et al. Impact of mutational studies on the diagnosis and the outcome of high-risk myelodysplastic syndromes and secondary acute myeloid leukemia patients treated with 5-azacytidine. Oncotarget. 2018;9(27):19342–19355.
   PubMedGoogle Scholar
• Bao ZH, Zhao HG, Yu HE. Clinical efficacy and prognostic factors of decitabine for treatment of myelodysplastic syndrome. Zhongguo Shi Yan Xue ye Xue za Zhi. 2018;26(6):1702–1707.
   PubMedGoogle Scholar
• Teresa Cedena M, Rapado I, Santos-Lozano A, et al. Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes. Oncotarget. 2017;8(63):106948–106961.
   PubMedGoogle Scholar
• Chang CK, Zhao YS, Xu F, et al. TP53 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes. Br J Haematol. 2017;176(4):600–608.
   PubMed Web of Science ®Google Scholar
• Tobiasson M, McLornan DP, Karimi M, et al. Mutations in histone modulators are associated with prolonged survival during azacitidine therapy [article.]. Oncotarget. 2016;7(16):22103–22115.
   PubMedGoogle Scholar
• Jung SH, Kim YJ, Yim SH, et al. Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome. Oncotarget. 2016;7(34):55264–55275.
   PubMedGoogle Scholar
• Traina F, Visconte V, Elson P, et al. Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. Leukemia. 2014;28(1):78–87.
   PubMed Web of Science ®Google Scholar
• Itzykson R, Kosmider O, Cluzeau T, Groupe Francophone des Myelodysplasies (GFM), et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia. 2011;25(7):1147–1152.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Haase D, Santini V, ESMO Guidelines Committee. et al. Myelodysplastic syndromes: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(2):142–156.
   PubMed Web of Science ®Google Scholar
• Du M, Zhou F, Jin R, et al. Mutations in the DNA methylation pathway predict clinical efficacy to hypomethylating agents in myelodysplastic syndromes: a meta-analysis. Leuk Res. 2019 May;80:11–18.
   PubMed Web of Science ®Google Scholar
• Bernard E, Nannya Y, Hasserjian RP, et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med. 2020;26(10):1549–1556.
   PubMed Web of Science ®Google Scholar
• Chen CY, Lin LI, Tang JL, et al. RUNX1 gene mutation in primary myelodysplastic syndrome-the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome. Br J Haematol. 2007;139(3):405–414.
   PubMed Web of Science ®Google Scholar
• Malcovati L, Stevenson K, Papaemmanuil E, et al. SF3B1-mutant MDS as a distinct disease subtype: a proposal from the international working group for the prognosis of MDS. Blood. 2020;136(2):157–170.
   PubMed Web of Science ®Google Scholar
• Thol F, Kade S, Schlarmann C, et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood. 2012;119(15):3578–3584.
   PubMed Web of Science ®Google Scholar